Barrier-breaking effects of ultrasonic cavitation for drug delivery and biomarker release

Wei, Jianpeng; Shen, Yuanyuan; Chen, Siping; Chen, Xin

doi:10.1016/j.ultsonch.2023.106346

Cited by 19 publications

(7 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in subcutaneous PC-3 prostate cancer xenografts, doxorubicin concentrations following IV infusion decrease exponentially with increasing distance from blood vessels and failed to kill cancer cells [ 50 ]. Molecular biomarkers including driver mutations within tumor cells, plasma membranes enveloping cell-level biomarkers, blood vessel endothelium, and separating tissue-level biomarkers within the TME are less likely to create neoantigens available to immune surveillance in tumor not exposed to tumoricidal concentrations of drug [ 48 , 51 , 52 ]. Taken together, these observations suggest that multiple routes of drug administration to solid tumors may be required to maximize primary tumor eradication and reduce metastatic disease [ 44 , 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies

diZerega,

Maulhardt,

Verco

et al. 2024

Oncol Ther

View full text Add to dashboard Cite

This review summarizes development of large surface area microparticle paclitaxel (LSAM-PTX) and docetaxel (LSAM-DTX) for local treatment of primary carcinomas with emphasis on immunomodulation. Intratumoral (IT) delivery of LSAM-PTX and LSAM-DTX provides continuous, therapeutic drug levels for several weeks. Preclinical studies and clinical trials reported a reduction in tumor volume (TV) and immunomodulation in primary tumor and peripheral blood with increases in innate and adaptive immune cells and decreases in suppressor cells. Increased levels of checkpoint expression of immune cells occurred in clinical trials of high-risk non-muscle-invasive bladder cancer (LSAM-DTX) and unresectable localized pancreatic cancer (LSAM-PTX). TV reduction and increases in immune effector cells occurred following IT LSAM-DTX and IT LSAM-PTX together with anti-mCTLA-4 and anti-mPD-1, respectively. Synergistic benefits from combinatorial therapy in a 4T1-Luc breast cancer model included reduction of metastasis with IT LSAM-DTX + anti-mCTLA-4. IT LSAM-PTX and LSAM-DTX are tumoricidal, immune enhancing, and may improve solid tumor response to immune checkpoint inhibitors without additional systemic toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies

diZerega,

Maulhardt,

Verco

et al. 2024

Oncol Ther

View full text Add to dashboard Cite

show abstract

“…The destruction of cell walls and membranes interrupts photosynthesis, inhibits cell division and the cell cycle, and reduces the growth rate of algae. 81 …”

Section: Progress In the Research And Application Of Typical Physical...mentioning

confidence: 99%

Principles and research progress of physical prevention and control technologies for algae in eutrophic water

Wang,

Zhu,

Wang

et al. 2024

iScience

View full text Add to dashboard Cite

“…Nonspecific nanomedicine accumulation poses significant challenges in cancer treatment as they can inadvertently lead to adverse side effects by accumulating in healthy cells [54,55]. Furthermore, the cell membrane acts as a biological barrier, impeding efficient drug delivery to cancer cells [56]. The barrier function of the cell membrane hinders the penetration and absorption of therapeutic agents, making it challenging to achieve the desired drug concentration in cancer cells.…”

Section: Cancer-targeting Ligandmentioning

confidence: 99%

Role of Functionalized Peptides in Nanomedicine for Effective Cancer Therapy

Kim,

Park

2024

Biomedicines

View full text Add to dashboard Cite

Peptide-functionalized nanomedicine, which addresses the challenges of specificity and efficacy in drug delivery, is emerging as a pivotal approach for cancer therapy. Globally, cancer remains a leading cause of mortality, and conventional treatments, such as chemotherapy, often lack precision and cause adverse effects. The integration of peptides into nanomedicine offers a promising solution for enhancing the targeting and delivery of therapeutic agents. This review focuses on the three primary applications of peptides: cancer cell-targeting ligands, building blocks for self-assembling nanostructures, and elements of stimuli-responsive systems. Nanoparticles modified with peptides improved targeting of cancer cells, minimized damage to healthy tissues, and optimized drug delivery. The versatility of self-assembled peptide structures makes them an innovative vehicle for drug delivery by leveraging their biocompatibility and diverse nanoarchitectures. In particular, the mechanism of cell death induced by self-assembled structures offers a novel approach to cancer therapy. In addition, peptides in stimuli-responsive systems enable precise drug release in response to specific conditions in the tumor microenvironment. The use of peptides in nanomedicine not only augments the efficacy and safety of cancer treatments but also suggests new research directions. In this review, we introduce systems and functionalization methods using peptides or peptide-modified nanoparticles to overcome challenges in the treatment of specific cancers, including breast cancer, lung cancer, colon cancer, prostate cancer, pancreatic cancer, liver cancer, skin cancer, glioma, osteosarcoma, and cervical cancer.

show abstract

Barrier-breaking effects of ultrasonic cavitation for drug delivery and biomarker release

Cited by 19 publications

References 152 publications

Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies

Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies

Principles and research progress of physical prevention and control technologies for algae in eutrophic water

Role of Functionalized Peptides in Nanomedicine for Effective Cancer Therapy

Contact Info

Product

Resources

About